ARTICLE | Clinical News
AV0113 regulatory update
March 11, 2013 7:00 AM UTC
EMA granted Orphan Drug designation for Activartis' AV0113 to treat glioma. The dendritic cell cancer vaccine is in Phase II testing to treat glioblastoma multiforme (GBM). ...